$60M donation will fund cardiovascular institute at Vancouver General Hospital
From the left, Vivian Eliopoulos, president and CEO of Vancouver Coastal Health, Ajay Dilawri, co-founder of the Dilawri Foundation, Angela Chapman, president and CEO of the VGH and UBC Hospital Foundation, and Dr. David Wood, head of cardiology at Vancouver General Hospital and the University of British Columbia Hospital, pose for a picture at an event unveiling a $60-million donation by the Dilawri Foundation for a new cardiovascular health institute and a research innovation fund in Vancouver on Thursday, June 5, 2025. (Darryl Greer / The Canadian Press)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
37 minutes ago
- CBC
Nunavik's 14 mayors call for public health emergency over tuberculosis cases
Social Sharing The mayors of 14 Inuit communities in northern Quebec are demanding the provincial government declare a public health emergency as tuberculosis cases in Nunavik reach the highest reported level in recent history. In a letter Monday to Quebec Health Minister Christian Dubé, the mayors wrote that two issues precipitated the demand: an "unprecedented surge" in tuberculosis cases, and what they say is a plan by the province to cut back on infectious disease resources for Nunavik. CBC News wasn't immediately able to verify the cuts in question. Last year, the region's health board reported 95 cases of tuberculosis. To date in 2025, the mayors wrote, 40 cases have been reported. "These statistics are a direct reflection of colonial systemic racism that continues to dictate health policy and resource allocation in Quebec," the mayors wrote. "Inuit in Nunavik are not treated as equal citizens under Quebec's health system." Nunavik faces record surge in tuberculosis cases 1 month ago Duration 2:55 In March, the Nunavik Regional Board of Health and Social Services said in a news release that six out of the 14 communities were experiencing active outbreaks. Aside from being the highest case count, it was also the highest number of simultaneous outbreaks they had recorded. The situation is "out of control," said Adamie Kalingo, the mayor of Ivujivik, a Nunavik village with about 400 residents. "Now we have a very high rate of tuberculosis cases, which we think could have been avoided if the health system could have worked with us more rapidly," Kalingo said. The mayors listed nine calls to action for the Quebec government, including sending emergency medical resources to the region. They are also calling for urgent investment in water, housing and utility infrastructure, as tuberculosis can spread more easily among overcrowded households. "It's difficult to gauge who has it or who hasn't. It's a very difficult situation, and it is all that much more dangerous for children, for elders that get a lot of [visits] from friends and relatives," Kalingo said. "So there is the matter of spreading it freely among friends and relatives. It's very hard to try to stop it." The mayors collectively described the state of Nunavik's health services as "abhorrent," alleging there aren't enough qualified staff, there are high levels of burnout and turnover, and basic health resources for tuberculosis, like testing kits and lab services, aren't readily available — if they're available at all. "Medical resources currently in place are insufficient to maintain regular large-scale screening needed to slow the spread," the mayors wrote. They pointed to the quick response of the health-care system when dealing with recent outbreaks in Montreal as an example of what Nunavik needs. "Inuit from Nunavik have died of TB in very recent years, and according to physicians working in the region, we will see more severe cases and more deaths unless the crisis is addressed with the resources needed," they wrote.
CTV News
an hour ago
- CTV News
Quebec to invest $10M in company developing Canadian-made satellite launch technology
Quebec Premier Francois Legault looks through a hand-held thermal imager during a tour of Thales Canada Defense and Security Optronics in Montreal on Monday, June 9, 2025. (Christinne Muschi/The Canadian Press) MONTREAL — Quebec premier François Legault says the province will invest $10 million in a Montreal-area company that is developing a system to launch small satellites into space. Legault announced the investment in Reaction Dynamics at the company's facility in Longueuil. Economy Minister Christine Fréchette says the investment will allow the company to begin launching microsatellites into orbit from Canada as early as 2027. Reaction Dynamics plans to use a rocket called Aurora to launch the satellites. Company President Bachar Elzein says the hybrid propulsion system they use contains fewer pieces than traditional rocket motors, making them safer and simpler to produce. Legault said Canada is the only country in the G7 without domestic satellite launching capacity. A first demonstration flight is expected to take place later this year. This report by The Canadian Press was first published June 9, 2025. By Morgan Lowrie, The Canadian Press
Globe and Mail
an hour ago
- Globe and Mail
MedX Announces Final Closing of Non-Brokered Private Placement
MedX Health Corp. (' MedX ' or the ' Company ') (TSX-V: MDX) is pleased to announce that, further to its Press Releases dated April 7, and May 22, 2025, announcing an Initial Closing and further Closing, it has completed a final Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025. The Final Closing comprised the issuance of 8,678,571 Units (as described below) and raised cash proceeds of $607,500, bringing the total amount raised in the Placement to $2,063,500. Securities issued are subject to a regulatory 'hold' period of four months and one day from the date of issuance. Under this Non-Brokered Private Placement, the Company issued a total of 29,478,571 Units at $0.07 per Unit ('Unit'). Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant (' Warrant ( s)'), exercisable to purchase One (1) further Common Share at the price of $0.09, during the period of one year commencing on the date of issuance. Three Insiders participated in this Placement to the extent of $500,000, for the acquisition of a total of 7,142,857 Units. In connection with the issuance of Units to those Insiders, the Company relies on exemptions from formal valuation and minority shareholder approval requirements set out in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (' MI 61-101 '). as (i) the fair market value of the proposed placement to the Insiders does not exceed 25% of the market capitalization of the Company and (ii) the conditions in section 5.7(1)(a), section 5.7(1)(b) and section 5.7(1)(e) of MI 61-101 are met. Qualified agents received total cash commissions of $15,880, (equal to 8% of the gross proceeds received by the Company from the sale of the Units to subscribers introduced by such agent(s)), and 226,857 agent's warrants (' Agent's Warrant(s) ') (equal to 8% of subscriptions introduced by such agent(s)). Each Agent's Warrant, which is non-transferable, entitles the holder to acquire, at the price of CAD$0.07, a unit, comprised of One (1) fully paid Common Share and one (1) non-transferable share purchase warrant (' Agent's Share Purchase Warrant '), entitling the holder to acquire one additional Common Share at the price of CAD$0.09. The Agent's Warrants and any Agent's Share Purchase Warrants that may be issued pursuant to exercise of an Agent's Warrant, if not exercised, will expire one year following the date of issuance. Funds raised in this Placement are being be directed towards continuing development of the Company's leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes. About MedX Health Corp.: MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union and Turkey. Visit This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
